MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
10.08
+0.13
+1.31%
Opening 11:44 06/25 EDT
OPEN
9.90
PREV CLOSE
9.95
HIGH
10.23
LOW
9.89
VOLUME
338.10K
TURNOVER
--
52 WEEK HIGH
11.66
52 WEEK LOW
4.155
MARKET CAP
1.70B
P/E (TTM)
-3.2133
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VIR last week (0615-0619)?
Weekly Report · 3d ago
Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data
Simply Wall St · 4d ago
Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?
Simply Wall St · 06/18 05:29
Weekly Report: what happened at VIR last week (0608-0612)?
Weekly Report · 06/15 10:30
Assessing Vir Biotechnology (VIR) Valuation As Timothy Coughlin Takes Board And Audit Committee Roles
Simply Wall St · 06/11 14:34
Vir Biotechnology Is Maintained at Overweight by Morgan Stanley
Dow Jones · 06/11 12:40
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27
Benzinga · 06/11 12:30
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
TipRanks · 06/11 11:53
More
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Webull offers Vir Biotechnology Inc stock information, including NASDAQ: VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.